Literature DB >> 24038328

MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.

Elisa Benasciutti1, Elisabetta Mariani, Laura Oliva, Maria Scolari, Egon Perilli, Emmanuele Barras, Enrico Milan, Ugo Orfanelli, Nicola L Fazzalari, Lara Campana, Annalisa Capobianco, Luc Otten, Francesca Particelli, Hans Acha-Orbea, Fabio Baruffaldi, Roberta Faccio, Roberto Sitia, Walter Reith, Simone Cenci.   

Abstract

The molecular networks controlling bone homeostasis are not fully understood. The common evolution of bone and adaptive immunity encourages the investigation of shared regulatory circuits. MHC Class II Transactivator (CIITA) is a master transcriptional co-activator believed to be exclusively dedicated for antigen presentation. CIITA is expressed in osteoclast precursors, and its expression is accentuated in osteoporotic mice. We thus asked whether CIITA plays a role in bone biology. To this aim, we fully characterized the bone phenotype of two mouse models of CIITA overexpression, respectively systemic and restricted to the monocyte-osteoclast lineage. Both CIITA-overexpressing mouse models revealed severe spontaneous osteoporosis, as assessed by micro-computed tomography and histomorphometry, associated with increased osteoclast numbers and enhanced in vivo bone resorption, whereas osteoblast numbers and in vivo bone-forming activity were unaffected. To understand the underlying cellular and molecular bases, we investigated ex vivo the differentiation of mutant bone marrow monocytes into osteoclasts and immune effectors, as well as osteoclastogenic signaling pathways. CIITA-overexpressing monocytes differentiated normally into effector macrophages or dendritic cells but showed enhanced osteoclastogenesis, whereas CIITA ablation suppressed osteoclast differentiation. Increased c-fms and receptor activator of NF-κB (RANK) signaling underlay enhanced osteoclast differentiation from CIITA-overexpressing precursors. Moreover, by extending selected phenotypic and cellular analyses to additional genetic mouse models, namely MHC Class II deficient mice and a transgenic mouse line lacking a specific CIITA promoter and re-expressing CIITA in the thymus, we excluded MHC Class II expression and T cells from contributing to the observed skeletal phenotype. Altogether, our study provides compelling genetic evidence that CIITA, the molecular switch of antigen presentation, plays a novel, unexpected function in skeletal homeostasis, independent of MHC Class II expression and T cells, by exerting a selective and intrinsic control of osteoclast differentiation and bone resorption in vivo.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ADAPTIVE IMMUNITY; BONE; CIITA; MHC CLASS II; OSTEOCLAST DIFFERENTIATION

Mesh:

Substances:

Year:  2014        PMID: 24038328     DOI: 10.1002/jbmr.2090

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

Review 1.  Osteoimmunology: from mice to humans.

Authors:  Patrizia D'Amelio; Francesca Sassi
Journal:  Bonekey Rep       Date:  2016-05-18

2.  CIITA: a master regulator of adaptive immunity shows its innate side in the bone.

Authors:  Mary C Nakamura
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

Review 3.  Cytomegalovirus infection: friend or foe in rheumatoid arthritis?

Authors:  Jean-Luc Davignon; Bernard Combe; Alain Cantagrel
Journal:  Arthritis Res Ther       Date:  2021-01-07       Impact factor: 5.156

4.  Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.

Authors:  Yan Zhou; Dong Yang; Qingcheng Yang; Xiaobin Lv; Wentao Huang; Zhenhua Zhou; Yaling Wang; Zhichang Zhang; Ting Yuan; Xiaomin Ding; Lina Tang; Jianjun Zhang; Junyi Yin; Yujing Huang; Wenxi Yu; Yonggang Wang; Chenliang Zhou; Yang Su; Aina He; Yuanjue Sun; Zan Shen; Binzhi Qian; Wei Meng; Jia Fei; Yang Yao; Xinghua Pan; Peizhan Chen; Haiyan Hu
Journal:  Nat Commun       Date:  2020-12-10       Impact factor: 14.919

5.  Serum-derived extracellular vesicles inhibit osteoclastogenesis in active-phase patients with SAPHO syndrome.

Authors:  Yanpan Gao; Yanyu Chen; Lun Wang; Chen Li; Wei Ge
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-04-16       Impact factor: 5.346

6.  Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.

Authors:  Huan Liu; Jin He; Rozita Bagheri-Yarmand; Zongwei Li; Rui Liu; Zhiming Wang; Duc-Hiep Bach; Yung-Hsing Huang; Pei Lin; Theresa A Guise; Robert F Gagel; Jing Yang
Journal:  Nat Commun       Date:  2022-06-27       Impact factor: 17.694

Review 7.  Role of the major histocompatibility complex class II protein presentation pathway in bone immunity imbalance in postmenopausal osteoporosis.

Authors:  Xiaoning Wang; Xin Zhang; Yidan Han; Xinwei Duan; Jianchang Wang; Hui Yan; Shanshan Wang; Yunteng Xu; Zaishi Zhu; Lili Wang; Yanfeng Huang; Qing Lin; Xue Tan; Junkuan Zhuo; Haifeng Zhang; Min Mao; Weiying Gou; Zhouping Yi; Xihai Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-11       Impact factor: 6.055

8.  Human Monocyte-Derived Osteoclasts Are Targeted by Staphylococcal Pore-Forming Toxins and Superantigens.

Authors:  Sacha Flammier; Jean-Philippe Rasigade; Cédric Badiou; Thomas Henry; François Vandenesch; Frédéric Laurent; Sophie Trouillet-Assant
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.